Business


left GSK in 2006 to pursue a career in technology and innovation consulting where he assists compa- nies in the understanding and adoption of open innovation and externalisation of science in order to access global capability, capacity and knowledge capital. He is the author of several papers and patents in the areas of medicinal and computation- al chemistry, laboratory automation, microfluidics and novel business models. Dr Pardoe can be con- tacted at david.pardoe@paconsulting.com


Dr Jackie Hunter has worked in the pharmaceutical industry for more than 25 years and was the former SVP and Head of the Neurology and Gastrointestinal Centre of Excellence for Drug Discovery at GlaxoSmithKline. In 2008 she became Head of Science Environment Development where she was responsible for developing GSK’s Open Innovation strategy for Pharmaceutical R&D. In 2010 she left GSK forming Pharmivation Ltd to concentrate on open innovation in bioscience. She is Non-Executive Director of Proximagen Neuroscience, was named as one of 2010’s Women of Outstanding Achievement in Science, Engineering and Technology for her contribution to innovation and entrepreneurship and was awarded the CBE in June for her contributions to the phar- maceutical industry.


Dr Robert M Cooke received his BSc and PhD in chemistry from the University of Sydney. Following a post-doctorate in the Department of Biochemistry at Oxford, Dr Cooke joined Glaxo in 1989. Since then he has led UK and transatlantic departments in a range of disciplines (including protein production, structural biology, computa- tional chemistry and analytical chemistry). He has chaired matrix committees for portfolios of drug discovery programmes and pioneered external col- laborations. He initiated the Structural Genomics Consortium, chairing the SAB throughout its first phase of operations, and is now a Board member and Director of the SGC company. Dr Cooke is also on the advisory boards of several academic ventures including the European Bioinformatics Institute. Dr Cooke can be contacted at rob.m.cooke@gsk.com


Dr Paul Barrett has worked in the consulting industry with PA Consulting Group for 18 years, specialising in assignments in innovation and tech- nology management for international clients in a variety of sectors including healthcare, government and consumer goods. His current areas of activity include R&D transformation, open innovation,


Drug Discovery World Winter 2010/11 17


development of innovation strategy and portfolio management. Prior to PA, his industrial experience was with process, analytical and medical instru- mentation companies in R&D and Marketing management and Business Unit leadership. Dr Barrett has a PhD in Low Temperature Physics from Bristol University and an MBA from the University of Warwick.


References 1 Mullin, R. Chemical and Engineering News, 88 (8), 12- 18, 2010. 2 Cooper, RG, Edgett, SJ, Kleinschmidt, EJ. In: Portfolio Management for New Products, Addison-Wesley Longman Inc. MA,1998. 3 Porkolab, L. Drug Disc. Today, 7 (4),230-231, 2002.


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80